Mutations in the gene encoding peripheral myelin protein 22 (PMP22) account for several inherited peripheral neuropathies in humans. We now show that transgenic mice expressing antisense PMP22 RNA exhibit modestly reduced levels of PMP22 together with a phenotype that is reminiscent of hereditary neuropathy with liability to pressure palsies (HNPP), a human disease caused by a 1.5-Mb deletion of a chromosome 17 region that contains the PMP22 gene. Transgenic antisense homozygotes display a striking movement disorder and a slowing of nerve conduction that worsens with age. Morphological analysis of peripheral nerves demonstrates that a subset of axons have thickened myelin sheaths and tomacula in young adults, with significant myelin degeneration detected in older animals. Together with other recent work, these data suggest that dosage of the PMP22 gene alone underlies the pathophysiology observed in HNPP and related disorders.
INTRODUCTION
The myelin sheath is a spirally wrapped organelle that surrounds many peripheral and central axons in vertebrates, allowing rapid, saltatory conduction of neuronal action potentials (Lemke, 1992) . In the PNS, myelin is elaborated by Schwann cells, and in the CNS, it is elaborated by oligodendrocytes. While a subset of proteins is common to both central and peripheral myelin, specific proteins are preferentially expressed in either the CNS (e.g., the proteolipid protein, PLP) or the periphery (e.g., protein zero, P 0 ) (Lemke, 1992) . Among the latter is peripheral myelin protein 22 (PMP22), a 22-kDa glycoprotein largely restricted to the compacted regions of the PNS myelin sheath. An integral membrane protein with four predicted transmembrane domains, PMP22 is related in its secondary structure to gap junction connexins and other tetraspan proteins, including PLP (Schneider et al., 1988; Spreyer et al., 1991; Welcher et al., 1991; Suter and Snipes, 1995) . Although myelinating Schwann cells are the most prominent site of PMP22 expression, the protein is also expressed in some nonneural tissues during development and in the adult, and it is expressed in motor neurons of the cranial nerve motor nuclei and in the anterior horn of the spinal cord (Parmantier et al., 1993) . The particularly high levels of expression observed in myelinating Schwann cells are thought to be due to the influence of a strong Schwann cell-specific alernative PMP22 promoter (Suter et al., 1994) . Although the function of PMP22 is unclear, it may multimerize to form a channel or pore for ions or small metabolites. Recent data suggest that it is essential to myelin structural stability (Adlkofer et al., 1995) and that it may also induce growth arrest in Schwann cells (Zoidl et al., 1994) .
PMP22 has been directly implicated in several dominantly inherited peripheral neuropathies, which are among the most common of inherited diseases in humans (Suter and Snipes, 1995) . The PMP22 gene is located at chromosome 17p11.2-p12, in a 1.5-Mb region (Matsunami et al., 1992; Patel et al., 1992; Timmerman et al., 1992) that undergoes either intrachromosomal duplication in the case of Charcot-Marie-Tooth disease type 1A (CMT1A) (Lupski et al., 1991) or intrachromosomal deletion in the case of hereditary neuropathy with liability to pressure palsies (HNPP or Tomaculous neuropathy; Chance et al., 1993) . These two diseases are the reciprocal results of an unequal crossing-over event between misaligned flanking repeat sequences at either end of the duplicated/deleted region. A recombination hot spot exists within the flanking repeat elements near a mariner transposon-like element, and it has been proposed that the latter may be involved in the crossover process (Reiter et al., 1996) . Although the 1.5-Mb region almost certainly contains numerous genes in addition to the PMP22 gene, this gene has been directly tied to the human neuropathies through studies on mouse Trembler and TremblerJ mutants (Suter et al., 1992a,b) , in which point mutations in PMP22 lead to phenotypes similar to those observed in CMT1A. In addition, multiple human patients with CMT1A and related peripheral neuropathies have also been found to carry point mutations in the PMP22 gene, rather than the large chromosomal duplication (Valentijn et al., 1992; Roa et al., 1993; Scherer and Chance, 1995) .
CMT occurs with a prevalence of 1:2500 and the major form is the CMT1A subtype (Wise et al., 1993) . This disease is characterized by progressive distal muscle weakness, decreased peripheral nerve conduction velocities and segmental demyelination/remyelination (Lupski et al., 1993) . A feature frequently observed in biopsies is the formation of ''onion bulbs''-structures formed around peripheral axons as a consequence of repeated demyelination and remyelination (Suter and Snipes, 1995) . The reciprocal disease, HNPP, is frequently misdiagnosed and has a more transient phenotype. It is characterized by acute or recurrent muscle palsy and paraesthesias caused by focal neuropathy at vulnerable sites of nerve compression (Meier and Moll, 1982) . A characteristic of HNPP is the multifocal formation of myelin thickenings (Tomaculum, Latin 5 sausage) which are a consequence of aberrant myelination.
In order to characterize the effect of PMP22 gene dosage on myelin stability and function, and to assess whether reduced dosage of the PMP22 gene alone accounts for HNPP, we generated a line of transgenic mice in which the peripheral myelin-specific promoter from the P 0 gene was used to drive expression of PMP22 antisense RNA. We show that for a modest (15%) decrease in levels of endogenous PMP 22 expression, the animals develop a striking gait disorder with an apparent proprioceptive deficit. Neurophysiological studies reveal prolonged F-wave responses and a slowing of nerve conduction that worsens with age. Together with a recent study showing clear HNPP neuropathy in PMP 22 knock-out mice (Adlkofer et al., 1995) , our data indicate that HNPP occurs as a consequence of reduced PMP22 gene dosage.
RESULTS

Generation of PMP22 Antisense Mice
In order to analyze the effect of reduced PMP22 gene dosage on myelin integrity we generated transgenic mice using the PMP22 antisense construct shown in Fig.  1 . We employed the 1.1-kb promoter from the rat P 0 gene (Lemke et al., 1988) in order to restrict expression of the transgene to myelinating Schwann cells, excluding other cell types and tissues. This strategy has been used successfully in several previous transgenic studies, and it results in transgene expression specific to myelinating Schwann cells (Messing et al., 1992 (Messing et al., , 1994 Weinstein et al., 1995) . The rat P 0 promoter, which contains the P 0 TATA box and carries the transcription start site and 46 base pairs of untranslated 58 RNA, was linked to a rat PMP22 antisense cDNA. The rat and mouse PMP22 sequences exhibit multiple extended stretches of contiguous nucleotide sequence identity, but the use of the rat cDNA also allows for the advantageous formation of small bulges in those regions where base pairing is not perfect. The construct also contained a BamHI-XhoI fragment from FIG. 1. Transgenic construct. The P 0 regulatory region (black box) extends from a HindIII site 1046 bp upstream of the rat transcription start site (arrow) to an ApaI site (converted to a HindIII site) located 46 bp downstream of this site. The PMP22 gene (gray box) is in the antisense orientation and is a HindIII-XbaI fragment from the plasmid described by Spreyer et al. (1991) . The transcribed rat antisense RNA spans the entire translated region of endogenous PMP22 and is 95% homologous to the mouse mRNA. The segment of rabbit b-globin gene (white box) contains the 38 end of the second exon followed by an intron, the third globin exon, and 38 untranslated RNA. Asterisks denote restriction sites in pBluescript polylinker used for linearization of DNA for microinjection. Restriction sites destroyed during cloning are outlined. the rabbit b-globin gene, which includes the last intron of this gene and its polyadenylation signal.
We obtained 15 antisense transgenic founder mice from microinjection of the antisense PMP22 construct into the male pronucleus of fertilized mouse eggs. Three animals developed phenotypes that were consistent with severe peripheral neuropathy (e.g., Giese et al., 1992) , including distal limb weakness, hind leg collapse upon lifting by the tail, and mild intention tremors. Two of these affected founders were unable to reproduce, and the third did not transmit the transgene. The remaining founder animals were bred with wild-type mates to generate the F1 generation, and where possible, male/female pairs were selected from the same litter to generate F2 animals. In one line, Tg117, we observed animals in the F2 generation that had a grossly exaggerated, high-stepping gait reminiscent of a peripheral neuropathy with a strong proprioceptive component. These animals are described in the following sections.
Behavioral Phenotype of Antisense PMP22 Mice
The behavioral phenotype observed in the established transgenic line was characterized by an unusual gait disorder in young animals and distal limb weakness with increasing age. The affected animals displayed an aberrant gait that was prominent in the hind limbs and was associated with an abnormally high step in which the limb was clutched at the height of the step. This was first observed at several weeks after birth, the time at which peripheral myelination is proceeding most vigorously, and worsened thereafter. A montage of video frames of an affected mouse completing one step cycle of movement is illustrated in Fig. 2 . As the rear limbs are elevated, the step is bizarrely high, with frequent tremor
FIG. 2.
Video montage of homozygous PMP22 antisense mouse. The frames show a transgenic mouse as it moves its right hind limb (highlighted) through one phase of motion (left to right, top to bottom). The exaggerated, high-stepping gait is the most pronounced aspect of the behavioral phenotype, and it is characteristic of several inherited peripheral neuropathies in humans. The total elapsed time for this particular step series is approximately 0.9 s, although the time period for a complete step in the PMP-22 antisense homozygotes was highly variable, due to variable lengths of time during which mice clutched their hind limbs at the top of the step (middle row).
before the limbs are forcibly returned to the supporting surface. In addition, the Tg117 homozygotes display a general reluctance to walk at all and tend to explore the environment with both forelimbs, radially from a single point, before stopping and returning to a crouched position. The phenotype was transmitted with Mendelian distribution over multiple generations and affected animals occurred in approximately one-quarter of each F2 litter, suggesting that the phenotype was present in animals homozygous for the transgene. This was subsequently confirmed by Southern blotting (Fig. 3) , which also indicated that the transgenic heterozygotes contained six copies of the transgene. Confirmation that the full-length transgene had integrated into the genome was obtained by PCR mapping of genomic DNA (not shown). Heterozygous animals were fertile and showed no obvious behavioral phenotype except when very old. In contrast, homozygotes could not breed, and animals were therefore bred for analysis from F1 littermates.
The Effect of Antisense PMP22 on Endogenous Levels of PMP22 mRNA
The level of antisense PMP22 gene transcript was assessed in the tissues of adult transgenic mice by RT-PCR. Although the transgene resulted in reduced levels of PMP22 mRNA (see below), we were unable to reproducibly detect the antisense transcript itself using a series of PCR primers that were specific for the transgene and not for endogenous PMP22. This transcript was never detected in any other tissues analyzed (brain, heart, liver, lung, muscle, and spleen; not shown). The inability to directly detect the antisense RNA is likely to result from two factors. First, the level of transgene expression appears to be relatively low (see below). Second, the mechanism of antisense inhibition of target transcripts relies on the formation of an RNA hybrid that is extremely labile and susceptible to rapid degradation by cellular ribonucleases, leading to very low steady-state levels of the antisense transcript itself. That the transgene is indeed expressed and that this expression is Schwann-cell-specific is indicated by (a) the electrophysiological, morphological, and behavioral phenotypes described in this study (see below), which demonstrate action confined to the peripheral nervous system and not the central nervous system; (b) the observed reduction in sciatic nerve PMP22 mRNA (see below); and (c) the similarity of the phenotype we describe to the phenotype reported by Adlkofer et al. (1995) in PMP22 knock-out mice. Although this is the first report in which the P 0 promoter has been used to regulate the expression of an antisense gene, previous studies have utilized this promoter for cell-specific and temporal expression of diphtheria toxin A chain and human growth hormone (Messing et al., 1992) , SV40 Large T antigen (Messing et al., 1994) and truncated SCIP (Weinstein et al., 1995) constructs, among others, in myelinating Schwann cells. The observed expression pattern for these transgenes is congruent with the expression pattern of endogenous P 0 , which is specific to Schwann cells (Lemke and Axel, 1985) .
In order to quantitate any change in the level of endogenous PMP22 mRNA, we analyzed transcript levels by RNase protection in three independent littermate groups of young adult (4-5 months) homozygous transgenic and wild-type animals (Table 1) . Quantitation of transcript levels is a more reliable index than protein levels, since PMP22 protein is deposited in the myelin sheath, which may be partially lost due to dysmyelinating pathology. An antisense probe was generated from a PstI-NheI fragment of the mouse PMP22 sequence and used in a comparative assay with FIG. 3. Genomic configuration of the PMP22 antisense gene in the transgenic line. Southern blots were performed on HindIII-digested liver DNA purified from wild-type, PMP22 heterozygotes, and PMP22 homozygotes. The DNA was probed with a 32 P-labeled P 0 promoter probe. The wild-type P 0 gene generates a 2.3-kb HindIII band (You et al., 1991) and the PMP22 hetero-and homozygotes generate an additional 1.1-kb band.
an antisense probe for the GAPDH transcript. The ratio of detectable levels of PMP22/GAPDH transcripts was compared in wild type litter mates and transgenic animals. Homozygous transgenic animals consistently exhibit a 15% reduction of PMP22 transcript in comparison to that seen in wild-type animals. This modest reduction is reflected in the moderate cellular and electrophysiological phenotypes discussed in the following sections.
Nerve Conduction Studies
Electrophysiologic data were recorded in groups of wild-type and homozygous antisense PMP22 mice. Select measures, including caudal, sural, and tibial nerve latencies, assessed sensory and motor function in isolated distal nerve segments, while F-wave latencies provided an index of motor conduction in long segments of the tibial nerve, including both distal and proximal regions.
At 3-5 months, there were no significant differences between groups in measures of distal nerve function. Although the caudal nerve latency was prolonged by 14% in PMP22 antisense mice, this difference failed to reach statistical significance (P 5 0.13) (Fig. 4A) . In contrast, at 7-9 months, distal caudal nerve compound latencies were prolonged by 23% in the PMP22 transgenic mice (P 5 0.02), and distal sural nerve latencies were prolonged by 24% (P 5 0.03). Tibial latencies were prolonged by 8%, but were not significantly different from those of wild-type controls (Fig. 4B) .
In contrast to compound distal latencies, F-wave latencies were significantly different in PMP22 transgenic mice at the 3-to 5-month time point. The mean minimum F-wave latency from 20 trials in the wild-type group was 5.5 ms, compared to 7.3 ms in the transgenic animals (n 5 20, P 5 0.001). Representative F-wave latencies depicted in Fig. 5 illustrate earlier minimum latencies in 2 wild-type animals compared to 2 PMP22 antisense transgenics. Delayed F-wave responses represent conduction velocity slowing and/or partial conduction block of the fastest motor fibers, thus allowing slower conducting fibers to constitute the response. Partial conduction block may therefore be responsible for the abnormal phenotype we observed. At 7-9 months, tibial F-wave responses were detectable in only one animal in either the PMP22 antisense or wild-type mice (n 5 16). The inability to record F-wave responses in both older wild-type and transgenic animals may be due to agerelated changes that affect proximal root integrity. Note. Average values from four separate RNase protection measurements from single adult animals of the indicated genotypes. In total, three homozygous, three wild-type, and two heterozygous mice were analyzed for PMP-22 mRNA levels relative to GAPDH mRNA; data from these independent assessments were highly consistent with the average values for the individuals displayed above.
FIG. 4.
Measurements of caudal, sural, and tibial nerve onset latencies in PMP22 antinsense homozygotes at 3-5 (A) and 7-9 months (B). Deficits in caudal and sural nerve conduction were statistically significant by age 7-9 months, with latencies prolonged by 23 and 24% compared to controls, respectively (P 5 0.02 and 0.03).
To clarify the effects of impaired conduction in the PNS and to assess possible effects of the PMP22 transgene in the CNS, we recorded evoked potentials in the somatosensory cortex following peripheral nerve stimulation and in visual cortex following stroboscopic stimulation. The onset of intracortical transmembrane current flow in primary somatosensory cortex was delayed by approximately 3 ms in the PMP22 transgenic animals (Fig. 6 ). In addition, the altered sensory conduction resulted in a distortion of the rising slope of the current flow and a reduction in the peak amplitude of the initial intracortical response. In contrast, the onset, amplitude, and pattern of the intracortical current flow associated with visual stimulation was essentially unchanged in the PMP22 and wild-type mice (Fig. 6) . These data are consistent with normal conduction in the myelinated visual pathways of the CNS and suggest that the deficit in cortical somatosensory evoked response is, as expected from the peripheral nerve specificity of the P 0 promoter, due to altered nerve conduction only in the PNS.
Morphological Analysis of Sciatic Nerve from Transgenic Mice
We analyzed the ultrastructure of the sciatic nerve, a major peripheral nerve, in antisense PMP22 homo-and heterozygotes and wild-type littermates. Aberrant myelin profiles were most readily detected at 7-9 months, the age group in which slower NCVs were consistently observed. At low (light microscope) resolution, there were only very modest apparent differences between the animals. Analysis of electron micrographs, however, revealed numerous aberrant myelin profiles in every homozygous animal examined (Fig. 7) . Prominent features included myelin thickening, corresponding to the tomaculous structures reported in human HNPP biopsies (Meier and Moll, 1982) and in PMP22 knock-out mice (Adlkofer et al., 1995) (Figs. 7A and 7C ). In addition, large whorls of membrane characteristic of myelin breakdown were also observed (Fig. 7B,D) . Profiles indicative of multiple rounds of Schwann cell demyelination and subsequent remyelination resulting in onion bulb structures were similarly prominent (Figs. 7E and 7F), as were examples of nearly complete demyelination (Figs. 7G and 7H ). Cytoplasmic inclusions containing collagen fibers can be seen between the uncompacted myelin sheaths in these latter profiles. No indication of aberrant myelination was observed in either transgenic heterozygotes or wild-type littermates.
FIG. 5.
Tibial F-wave minimum latencies in wild-type (top) and PMP22 antisense homozygotes (bottom). F-wave latencies were significantly prolonged in PMP22 antisense mice (P , 0.001) at age 3-5 months (representative F-wave traces of four different animals shown). Stimulus onset is marked by the arrowhead.
FIG. 6.
Intracortically recorded somatosensory and visual evoked potentials in wild-type and PMP22 antisense homozygotes. Onset of current flow in PMP22 transgenic mice following tibial nerve stimulation (SEP) was delayed approximately 3 ms compared to controls. In contrast, responses to visual stimuli (VEP) showed no differences between groups. Traces represent grand mean averages of 10 cerebral hemispheres in each group. Stimulus onset is marked by the arrowhead.
DISCUSSION
We have generated a transgenic mouse line that develops an easily recognized movement disorder that is in several respects similar to that seen in the human hereditary peripheral neuropathy HNPP. This phenotype is confined to the peripheral nervous system and is first apparent as a grossly exaggerated stepping motion with very mild tremor that progresses to severe distal limb weakness in older adults. This behavior is accompanied by reductions in F-wave responses and peripheral (but not central) nerve conduction velocities, and by aberrant myelin ultrastructure that becomes progressively more pronounced as mice age.
Genetic analysis of CMT1A and HNPP patients has confirmed findings in Trembler mice that implicate PMP22 as a candidate gene in the etiology of these diseases. It has been proposed that PMP22 gene dosage plays a prominent role in their development and that the precise stoichiometry of PMP22 in the peripheral myelin sheath relative to other myelin proteins may be critical to myelin stability. CMT1A is associated with an intra- (Lupski et al., 1991) . Adlkofer et al. (1995) confirm that PMP22 gene dosage is responsible for the phenotype observed in HNPP patients, and exclude the possibility that another gene in the deleted region plays a significant role in the disease process. PMP22 homozygous null mice develop a tomaculous neuropathy similar to that of HNPP (the human equivalent of PMP22 2 / 2 mice has not been reported) with very slow conduction velocities. The PMP22 2 / 2 mice form tomaculous myelin sheaths that eventually degenerate, leaving thin sheaths or bare axons.
The data presented above illustrate that transgenic mice with only modest reductions in PMP22 levels eventually develop many of these same features of HNPP, but with a longer time course and with reduced incidence of tomacula. Overall, there is a good correlation between the relative reduction in PMP22 RNA levels in antisense (15%), heterozygote knock-out (50%),
FIG. 7-Continued
and homozygote knock-out (100%) mice, and the relative severity of phenotype observed in terms of peripheral myelin ultrastructure and peripheral nerve conduction. Data from nerve conduction studies confirm a functional deficit in conduction velocity in antisense homozygotes, with slowing of large-diameter myelinated axons, in both sensory and motor fibers. The physiological deficits were not significant in distal nerve segments measured at 3-5 months, but became significant at later times. This apparent exacerbation over time may reflect worsening of a natural disease process and is a consistent feature of mild peripheral neuropathies in mice . A key factor in the manifestation of the electrophysiologic deficit was the length of axon measured, rather than the specific axonal segment. This was evidenced by the increased sensitivity of the tibial F-wave latency at the earlier time point. The prolonged F-wave latencies suggest that both proximal and distal nerve segments were involved. The observation that the antisense mice develop pronounced Fwave abnormalities is also consistent with focal conduction block by 3-5 months (Uncini et al., 1995) . The pattern of onset and extent of the decrease in nerve conduction correlate with the detection of general myelin pathology in the sciatic nerve.
The appearance of Schwann cell morphology in the antisense mice is also similar to the pathology reported by Adlkofer et al. (1995) in PMP22 2 / 2 mice. We observed both thickened myelin sheaths and onion bulb profiles, indicating myelin instability, as well as occasional examples of bare axons. Adlkofer et al. (1995) report that tomacula frequently developed in paranodal areas and we also observed numerous disrupted myelin profiles in these regions. We did not, however, observe any regions of sciatic nerve that had marked demyelination or any tomacula in teased nerve preparations. The phenotype observed in the homozygous antisense PMP22 mice seems to have components of the phenotypes observed in both the PMP22 2 / 2 and PMP22 1 / 2 mice (Adlkofer et al., 1995) , with generally reduced severity.
A recent report describes a transgenic rat line generated using a cosmid clone containing PMP22 (Sereda et al., 1996) . These animals overexpress PMP22 and develop a severe demyelinating neuropathy. Together with the results described above and those of Adlkofer et al. (1995) , these studies emphasize the remarkable sensitivity of myelin stability to PMP22 gene dosage, since either over-or underexpression by even modest amounts results in long-term myelin instability. Perturbation of normal stoichiometry in experimental animal models leads to phenotypes that closely resemble those observed in patients with either HNPP (Adlkofer et al., 1995) or CMT1A (Sereda et al., 1996) . These findings are reminiscent of work with certain other myelin membrane proteins, especially the proteolipid protein PLP, whose precise gene dosage has also been shown to be critical role for myelin stability (Griffiths et al., 1995) . Inherited over-or underexpression of PLP in humans leads to the severe CNS dysmyelinating condition Pelizaeus-Merzbacher disease (Suter and Snipes, 1995) . It is perhaps not a coincidence that both PMP22 and PLP are small tetraspan proteins that may form pores or channels essential for metabolic (perhaps ionic) equilibrium within myelinating cells. The exquisite sensitivity to gene dosage suggests that these proteins may function as part of multisubunit assemblies. The main emphasis of future studies must therefore be on elucidating the remaining components of these assemblies and on the molecular mechanisms underlying altered myelin protein stoichiometries within them.
EXPERIMENTAL METHODS
Construction of the Transgene
We used the rat P 0 promoter and regulatory region (a 1.1-kb HindIII fragment) described previously (Lemke et al., 1988) , in which the ApaI site present in the middle of the P 0 58 untranslated RNA was modified to a HindIII site with a linker. A modified pBluescript plasmid (Stratagene) containing this promoter fragment was linearized with SmaI (in the pBluescript polylinker downstream of HindIII) and dephosphorylated. In order to increase the probability of transgene expression, a blunted BamHI-XhoI fragment from the 38 end of the rabbit b-globin gene, which contains the last intron and poly(A) signal of this gene (see Fig. 1 ), was ligated into this vector. The resulting construct was digested at an EcoRV site between the P 0 promoter and the b-globin gene site and dephosphorylated. The rat PMP22 cDNA was digested from the CD25 plasmid (Spreyer et al., 1991) at the HindIII and XbaI sites, blunted, and ligated into the P 0 promoter-b-globin plasmid at the EcoRV site. Antisense orientation was confirmed by restriction mapping and sequencing.
The antisense PMP22 plasmid was digested with KpnI and SacI to liberate the transgene. The transgene fragment was purified from contaminating plasmid by gel electrophoresis in low-melting-point agarose. The isolated fragment was purified by Elutip elution (Schleicher and Schuell, Keene, NH) and precipitated twice with ethanol. The DNA was adjusted to a final concentration of 1.5 mg/ml in injection buffer (0.15 mM EDTA and 10 mM Tris, pH 7.5).
Generation of Transgenic Mice
Female CB6F1 mice were superovulated by IP injection of 5 IU of PMS (Sigma, St. Louis, MO), followed 42 h later with a second injection of human chorionic gonadotrophin (Sigma). The mice were bred with stud males, the fertilized eggs were harvested the following morning, and the male pronucleus was injected with 2 pl of DNA. The injected eggs were transplanted into pseudopregnant female ICR mice and allowed to develop through to birth. The mice were assessed for incorporation of the transgene after weaning by PCR analysis of genomic DNA isolated from tail tissue. Transgenespecific primers were designed 58 in the P 0 promoter and 38 in the antisense PMP22. Founders were identified and bred with isogenic mates. The genotype of F1 animals and of all subsequent generations was assessed by PCR.
Southern Blot Analysis
Genomic DNA was isolated from liver or tail as follows. One lobe of liver or a 2-cm length of tail was digested overnight in a buffer containing 50 mM Tris, pH 8.0, 100 mM EDTA, 100 mM NaCl, 1% SDS, and 25 mg/ml of Proteinase K at 55°C. The digest was extracted twice with phenol, twice with phenol/chloroform, and once with chloroform. An equal volume of ethanol cooled to 220°C was added to the extract and DNA was spooled at the interface with a glass loop. The DNA was rinsed on the loop in 70% ethanol and then dissolved in 10 mM Tris, pH 8.3, 1 mM EDTA by gentle agitation at 4°C for 48 h. Twenty micrograms of DNA was digested with HindIII and resolved on a 0.8% agarose gel. The DNA was transferred to a nylon membrane (MSI, Westboro, MA) under basic denaturing conditions. Membrane-bound DNA was renatured briefly and baked at 80°C for 2 h. The blot was prehybridized for 4 h and then hybridized overnight with a random primed 32 P-radiolabeled P 0 promoter cDNA, followed by washing at 65°C for 15 min twice in 23 SSC/1% SDS, and twice at 65°C for 10 min in 0.23 SSC/0.5% SDS. The blot was dried and exposed on a phosphoimaging cassette overnight. The image was read on a Molecular Dynamics Model 400 PhosphorImager (Sunnyvale, CA) and analyzed for phoshodensity using ImageQuant software (Molecular Dynamics).
RT-PCR Analysis of Transgene Expression
Total RNA was isolated from sciatic nerve, lung, brain, liver, kidney, and spleen of 6-month-old mice as described by Chomczynski and Sacchi (1987) . The RNA was subsequently treated with RQ1 RNase-free DNase (Promega, Madison WI) to remove any contaminating genomic DNA. All steps of the procedure were performed in the presence of RNAsin (Promega). For RT-PCR analysis cDNA was synthesized from total RNA using oligo(dT) primers and MLV reverse transcriptase (Gibco) at 42 or 48°C in a total volume of 20 µl. For sciatic nerves, all of the RNA extracted (approx. 0.5 µg) was reverse transcribed. One-quarter of the total cDNA was used as template for subsequent PCRs. To amplify the PMP22 transgene cDNA, primers spanning from the 38 end of the antisense PMP22 sequence (58-ATGCAC-GCTCAGAGCCTAGAC-38) to the third exon of the b-globin cassette (58-CAGCACAACAACCAGCAC-38) were used. This primer combination would detect specifically the spliced or unspliced antisense transgene. Primers to mouse cyclophilin (sense: 58-AGCGCTTC-CCAGATGAGA-38 and antisense: 58-CGGAGTCGA-CAATGATGA-38) were used as a positive control for cDNA synthesis. PCR amplification was performed in standard buffer containing 100 ng of each primer, 200 µM each dNTP, and 2.5 U Taq polymerase (PerkinElmer). Standard PCR parameters were denaturation at 94°C (45 s), annealing at 60°C (120 s), and extension at 72°C (90 s) for 30 cycles. PCR products were size separated on 2% agarose gels and visualized with ethidium bromide staining. All tissues contained amplified cyclophilin products; however, no products were detected in any tissue using the transgene-specific primers. The latter were used successfully to detect subpicogram amounts of antisense plasmid DNA by PCR. Other transgene-specific primer combinations were tested and also failed to amplify any product.
RNase Protection Analysis
RNase protection analysis was performed using a modification of Krieg and Melton (1987) . Radiolabeled ( 35 S-UTP) antisense and sense riboprobes for PMP22 and GAPDH were prepared from the coding regions of mouse PMP22 (PstI-NheI fragment: 518 bp, protects 402 bp) or GAPDH by in vitro transcription reactions with either T3 or T7 polymerase (Promega). The full-length riboprobes were resolved from unincorporated label and truncated probes on a 6% polyacrylamide gel containing 8 M urea. The probes were eluted from the gel and an aliquot was measured for cpm. RNase protection was performed using RPAII (Ambion). Ribo-probes (1 3 10 5 cpm) were incubated with 1 µg of total RNA extracted from the sciatic nerve (Chomczynski and Saachi, 1987) for 18 h at 42°C. Protected fragments were resolved on a 6% polyacrylamide gel containing 8 M urea. The gel was dried and the protected bands were quantitated by Molecular Dynamics imaging as described in the previous section.
Electron Microscopy
The preparation of sciatic nerve for light and electron microscopy was performed exactly as described in Weinstein et al. (1995) .
Electrophysiologic Methods
Mice expressing the PMP22 antisense construct (N 5 10) and wild-type littermate controls (N 5 10) were evaluated at two time points, ages 3-5 and 7-9 months. CNS recordings included visual and somatosensory evoked potentials, recorded at 3-5 months using standard procedures previously described (Michaelson et al., 1996) . PNS electrophysiologic measures included tibial, sural, and caudal nerve distal latencies and tibial F-wave latencies. Anesthesia was maintained using ketamine (50 mg/kg, ip) and xylazine (40 mg/kg, ip). PNS recordings utilized subcutaneous (platinumiridium) needle electrodes, achieving supramaximal stimulation with a constant voltage stimulator and a 50/s square wave pulse. In tibial nerve recordings, the active electrode was inserted subcutaneously over the intrinsic foot flexor muscles, with the stimulating cathode overlying the tibial nerve 5.0 mm proximal to the lateral malleolus. Orthodromic sural nerve recordings were obtained by placing the stimulating cathode over the ventrolateral plantar foot surface, recording at the insertion of the gastrocnemius muscle in the midline. Stimulation for the caudal nerve was 30 mm distal to the active recording electrode, which was 10 mm from the tail base.
Neuroelectric signals were impedance matched through a unity gain preamplifier and further differentially amplified with appropriate bandpass settings. The signals were digitized, and when necessary, averaged online. Latencies were scored from baseline using computer cursors. F-wave measurements utilized the minimum onset latency in 10 consecutive trials.
